SEC Form 4 · accession 0001209191-19-010273
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asaf Danziger
Officer — Chief Executive Officer · Director
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Feb 12, 2019 | M | 32,098 | $11.46 | A | 203,262 | D | |
| Ordinary SharesF1 | Feb 12, 2019 | S | 32,098 | $51.46 | D | 171,164 | D | |
| Ordinary SharesF1 | Feb 13, 2019 | M | 17,902 | $11.46 | A | 189,066 | D | |
| Ordinary SharesF1 | Feb 13, 2019 | S | 17,902 | $51.46 | D | 171,164 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF2 | $11.46 | Feb 12, 2019 | M | 32,098 | D | — | Feb 24, 2026 | Ordinary Shares | 32,098 | 67,902 | D |
| Options to Buy Ordinary SharesF2 | $11.46 | Feb 13, 2019 | M | 17,902 | D | — | Feb 24, 2026 | Ordinary Shares | 17,902 | 50,000 | D |
Explanation of responses
- F1Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.
- F2Fully vested and currently exercisable as of the date hereof.